Drug
Arct 021 Dose 1
Arct 021 Dose 1: highest development phase Phase 1/2, developed by Arcturus Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Arcturus Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARCT-021 Dose 1 NCT04480957 | Phase 1/2 | SARS-CoV-2 |
Latest
No recent events.
Follow Arct 021 Dose 1 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.